Personal Account
AbCellera Biologics

AbCellera Biologics

Biotechnology company

Company website
Foundation year

2012

Close date

2/10/2021

Profitability

125.8%

About

Total Funding 

$371.2M

AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics

Number of employees

101-250

Headquarters

Vancouver, British Columbia, Canada


2022 © All rights reserved

You can always come to our office to discuss any questions with our manager

Dubai

Sharjah Media City, Sharjah, UAE

USA

500 Delaware ave,
STE 1 #1960 Wilmington, DE, USA

Czech Republic

Czech Republic, Prague, Bilkova 855/19

The investment opportunities posted on this website's Pre-IPO section are private placements of securities that are not traded on the open market, subject to the ownership period requirements, and intended for investors who do not require liquid investments. Investments in private companies may be considered speculative, involving high risk, including the significant loss of investment risk. Investors must be able to afford to lose all their investments.